Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemia - Test2 - elhamkhani - TriplyDB

Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemia

Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemia

http://www.wikidata.org/entity/Q34876825

about

The Therapeutic Targets of miRNA in Hepatic Cancer Stem Cells Epigenetic regulators and their impact on therapy in acute myeloid leukemia Progress in epigenetic histone modification analysis by mass spectrometry for clinical investigations The complexity of epigenetic diseases Biological features and biomarkers in hepatocellular carcinoma Polycomb Group (PcG) Proteins and Human Cancers: Multifaceted Functions and Therapeutic Implications Advances in sarcoma diagnostics and treatment EZH2 in Bladder Cancer, a Promising Therapeutic Target Systematic chemical and molecular profiling of MLL-rearranged infant acute lymphoblastic leukemia reveals efficacy of romidepsin A covalently bound inhibitor triggers EZH2 degradation through CHIP-mediated ubiquitination.The molecular mechanics of mixed lineage leukemia.Polycomb genes, miRNA, and their deregulation in B-cell malignancies Cells adapt to the epigenomic disruption caused by histone deacetylase inhibitors through a coordinated, chromatin-mediated transcriptional response.Non-Canonical EZH2 Transcriptionally Activates RelB in Triple Negative Breast Cancer An Alternative Approach to ChIP-Seq Normalization Enables Detection of Genome-Wide Changes in Histone H3 Lysine 27 Trimethylation upon EZH2 Inhibition.Multicellular Tumor Spheroids Combined with Mass Spectrometric Histone Analysis To Evaluate Epigenetic Drugs.Rapid generation of drug-resistance alleles at endogenous loci using CRISPR-Cas9 indel mutagenesis.Acute myeloid leukemia requires Hhex to enable PRC2-mediated epigenetic repression of Cdkn2a Targeting EZH2 and PRC2 dependence as novel anticancer therapy.Ezh2 Controls an Early Hematopoietic Program and Growth and Survival Signaling in Early T Cell Precursor Acute Lymphoblastic Leukemia Targeting EZH2 for cancer therapy: progress and perspective.High Expression of CPT1A Predicts Adverse Outcomes: A Potential Therapeutic Target for Acute Myeloid Leukemia.MLL-Rearranged Leukemias-An Update on Science and Clinical Approaches.Emerging therapeutic targets in human acute myeloid leukemia (part 2) - bromodomain inhibition should be considered as a possible strategy for various patient subsets.Epigenetic Therapy in Acute Myeloid Leukemia: Current and Future Directions.Cancer stem cells in hepatocellular carcinoma: Therapeutic implications based on stem cell biology.Mutation spectra of histone methyltransferases with canonical SET domains and EZH2-targeted therapy.Transcriptional Selectivity of Epigenetic Therapy in Cancer.Inhibitors of Protein Methyltransferases and Demethylases.The emerging role of PI3K/AKT-mediated epigenetic regulation in cancer.Marked for death: targeting epigenetic changes in cancer.HMGA2 as a potential molecular target in KMT2A-AFF1-positive infant acute lymphoblastic leukaemia.EZH2 inhibitors: a patent review (2014-2016).Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains H3K27 Methylation: A Focal Point of Epigenetic Deregulation in Cancer.Epigenetic therapies by targeting aberrant histone methylome in AML: molecular mechanisms, current preclinical and clinical development.Histone H3K27 Trimethylation Modulates 5-Fluorouracil Resistance by Inhibiting PU.1 Binding to the DPYD Promoter.Novel orally bioavailable EZH1/2 dual inhibitors with greater antitumor efficacy than an EZH2 selective inhibitor.Targeting Enhancer of Zeste Homolog 2 as a promising strategy for cancer treatment Inactivation of Eed impedes MLL-AF9-mediated leukemogenesis through Cdkn2a-dependent and Cdkn2a-independent mechanisms in a murine model.

P2860

Q26749450-F114CA3C-DF09-42BC-86E0-9146437DDCC3 Q26765402-4FCB7320-C8B8-4E08-8E30-9217942FAA0E Q26781745-F908E6BB-DA9A-4E76-A908-2A38FACD9496 Q26784416-96EA0F86-062E-40A3-8B14-DCEA155F6B74 Q26799462-2A9078C6-F79C-4116-B0E0-1D216C6AB4F2 Q26801380-60F6DC7E-089D-4015-A2FB-7E383718E26A Q28069695-90913C3D-B9B6-4DE0-98A8-8998705056E2 Q28082054-15F30DC4-0DB3-4A26-9721-39C392827B13 Q28817780-40FA2114-7602-4200-B506-B9BD3DF008CB Q33626131-CB3D72CD-05F7-46E5-AA3B-A914D9672F54 Q34516051-1D1AF87F-25FA-48A5-89E8-7E75ED5E44A2 Q35103527-73D8F172-17B8-4B84-922F-FB4B1564C17A Q36067075-8E954504-C965-4368-A51A-327F75AC027B Q36169303-DB5EF905-29C8-4DA1-AE27-ACECD6E9E783 Q36201086-A8BDBB91-130F-4106-BC71-731A9DE6602D Q36279590-30730CFA-DF03-42E0-AD50-AB503BB34100 Q36288331-72E095AB-BBD7-4E9B-A745-38D0192C979E Q36432056-6900113D-8DD2-4050-987E-F32A980E5332 Q36445523-AF0AA2EA-2550-474A-A1CD-58FC204646DE Q36682938-1E49B8F5-DC0A-4779-84D6-A933308C5D52 Q37204063-96B5F537-6F1E-4EEB-BE5B-075B376E9126 Q37510247-34CE377B-B0E4-4A9A-9BB6-F43D5A8F8C5B Q37633585-B2E21E27-A1D8-4533-98C9-780255B3E150 Q38435352-A636246F-1B31-4AEC-8440-001B9E3F1F25 Q38537883-B708B44C-B885-4ACE-A781-600291FDAABD Q38540375-33268F0E-55DF-416B-AADC-19C0453DC23F Q38594002-9EB53A1D-F313-4C14-8B06-17467391674A Q38729313-D2E97122-6C1D-4FF8-A421-0834E919088E Q38740496-D91DE584-B811-4AD8-930D-8665EB29D942 Q38743320-6FB5011B-2140-410A-880D-C7368192EAB5 Q38747872-34B6BD2A-7CB4-4696-BDCE-18435F0FC1DC Q38832808-83ED58A9-D576-4691-8954-309573F75849 Q38844652-4553A885-BB70-4593-A190-52E5D2921CD1 Q38876767-1E3E3068-FB0C-4162-B6BC-3F02819AB4A2 Q38906678-9ECEC4EA-6BA3-4C95-BCB6-EBC0503314D5 Q38946185-E3536CE4-3004-4C9A-972D-762E65D213EB Q39437966-8BB7EAC2-5519-4C1A-B0CD-C30B2AB91FDC Q39457118-1EFF7F32-4A48-471B-A8EF-0A4382A3C931 Q40014635-3D42B5C7-C7B5-4311-87DE-CEDFBCE15B40 Q40789665-F7F32FE2-5CB8-48F4-9D16-086BCF89C462

P2860

Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemia

http://www.wikidata.org/entity/Q34876825

description

2014 nî lūn-bûn

@nan

2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Selective inhibition of EZH2 a ...... resses MLL-rearranged leukemia

@ast

Selective inhibition of EZH2 a ...... resses MLL-rearranged leukemia

@en

Selective inhibition of EZH2 a ...... resses MLL-rearranged leukemia

@nl

type

label

Selective inhibition of EZH2 a ...... resses MLL-rearranged leukemia

@ast

Selective inhibition of EZH2 a ...... resses MLL-rearranged leukemia

@en

Selective inhibition of EZH2 a ...... resses MLL-rearranged leukemia

@nl

prefLabel

Selective inhibition of EZH2 a ...... resses MLL-rearranged leukemia

@ast

Selective inhibition of EZH2 a ...... resses MLL-rearranged leukemia

@en

Selective inhibition of EZH2 a ...... resses MLL-rearranged leukemia

@nl

P1433

Q34876825-2625F481-A77F-4163-97C0-4D7F222BFFDF

P1476

Q34876825-A2523256-67F3-4F29-ADE9-E22C0A89A7F1

P2093

Q34876825-02E74BC9-405D-477D-B574-707F0E1034CF

Q34876825-07EFC7C5-A7D6-477B-A42E-A159AB4DA89C

Q34876825-564DFBF3-8DCD-4254-B287-9219A8421DE4

Q34876825-63868F5E-A00A-4CC9-A1C6-B27B8D94AACA

Q34876825-6407CD83-00F3-4669-ABFD-29647E2C002C

Q34876825-680DA6A5-F1DC-4718-806D-EF78FD318F19

Q34876825-68798BB5-9778-48F4-A09D-98BF1E2C6F30

Q34876825-8D301D10-34FB-4BCD-91DD-6A5BBE30AF22

Q34876825-9260A014-C8DC-4E02-AFB1-27DA646AC7D0

Q34876825-9F9DEF1E-5EDD-414C-B94D-A82D2904F031

P2860

Q34876825-01D13EAD-E435-4977-AE84-349F011454A1

Q34876825-03C4E65A-2746-49C4-88EA-8BE8182C8460

Q34876825-09C59BAA-A690-4177-BB49-377C7948BE78

Q34876825-10774911-652A-453A-B876-4AFA571FB312

Q34876825-151AFC8F-3BBD-4C14-B468-86DCA7447469

Q34876825-16F815A7-9FD0-4D24-B4C3-75017EBAD686

Q34876825-183B0DF3-6099-4843-85B9-1A6A3EBDDB7A

Q34876825-1B1779B3-05F1-4EFE-930E-E72A442AB1E9

Q34876825-1CADC3A9-4C14-4B98-87EA-C834F8F56D3A

Q34876825-1DD28134-6712-4F3E-88EA-50619C8A4DDF

P304

Q34876825-83159BB2-CE1A-4F1E-8FEC-C9062B5A197B

P31

Q34876825-73A2C651-8C76-47E5-8FDF-3B69D149AA04

P356

Q34876825-452BFEED-A544-4353-B562-6CF53A22B93D

P407

Q34876825-E3A42BEC-5E23-40E6-86BF-EFCB2108908A

P433

Q34876825-D3A2A265-639D-4169-8B19-FD4F2187EBB1

P478

Q34876825-1B171F3B-341E-4DE8-8B12-D436AF2C2D2B

P50

Q34876825-1C05415C-117C-4528-81E2-C3F1098EB8FB

Q34876825-418D33F5-D332-4F42-9635-957E41BCCFBD

P577

Q34876825-6741CCA8-3A12-4815-95F1-1959A021CD34

P5875

Q34876825-C56C8BF1-D207-423F-B23D-F1700672586E

P698

Q34876825-1DA78B37-66D9-4D80-8FD7-C6B723C73586

P921

Q34876825-FC168271-E13D-4E5E-92BA-8AAC89C68332

P932

Q34876825-D2102D82-3755-4A78-BB20-1759B430E42D

P356

BLOOD-2014-06-581082

P1433

P1476

Selective inhibition of EZH2 a ...... resses MLL-rearranged leukemia

@en

P2093

Anqi Ma

http://www.w3.org/2001/XMLSchema#string

Benjamin A Garcia

http://www.w3.org/2001/XMLSchema#string

Bowen Xu

http://www.w3.org/2001/XMLSchema#string

David F Allison

http://www.w3.org/2001/XMLSchema#string

Doan M On

http://www.w3.org/2001/XMLSchema#string

Fengling Li

http://www.w3.org/2001/XMLSchema#string

Jian Jin

http://www.w3.org/2001/XMLSchema#string

Kyle D Konze

http://www.w3.org/2001/XMLSchema#string

Ling Cai

http://www.w3.org/2001/XMLSchema#string

Masoud Vedadi

http://www.w3.org/2001/XMLSchema#string

P2860

Selective inhibition of BET bromodomains

An H3K36 methylation-engaging Tudor motif of polycomb-like proteins mediates PRC2 complex targeting

Covalent histone modifications--miswritten, misinterpreted and mis-erased in human cancers

EZH1 mediates methylation on histone H3 lysine 27 and complements EZH2 in maintaining stem cell identity and executing pluripotency

Haematopoietic malignancies caused by dysregulation of a chromatin-binding PHD finger

Structure of the Catalytic Domain of EZH2 Reveals Conformational Plasticity in Cofactor and Substrate Binding Sites and Explains Oncogenic Mutations

Structural Context of Disease-Associated Mutations and Putative Mechanism of Autoinhibition Revealed by X-Ray Crystallographic Analysis of the EZH2-SET Domain

Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin.

The language of covalent histone modifications

Histone methylation: a dynamic mark in health, disease and inheritance

P304

346-357

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2014-06-581082

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

125

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-11-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

268280999

http://www.w3.org/2001/XMLSchema#string

P698

25395428

http://www.w3.org/2001/XMLSchema#string

P921

P932

4287641

http://www.w3.org/2001/XMLSchema#string